PGEN Logo

Precigen, Inc. (PGEN) 

NASDAQ
Market Cap
$257.88M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
18 of 776
Rank in Industry
16 of 433

Largest Insider Buys in Sector

PGEN Stock Price History Chart

PGEN Stock Performance

About Precigen, Inc.

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional …

Insider Activity of Precigen, Inc.

Over the last 12 months, insiders at Precigen, Inc. have bought $20.19M and sold $136,327 worth of Precigen, Inc. stock.

On average, over the past 5 years, insiders at Precigen, Inc. have bought $28.55M and sold $10.09M worth of stock each year.

Highest buying activity among insiders over the last 12 months: KIRK RANDAL J () — $140.95M. Perez Jeffrey Thomas (SVP, IP Affairs) — $50,000.

The last purchase of 23,529,411 shares for transaction amount of $20M was made by KIRK RANDAL J () on 2024‑08‑09.

List of Insider Buy and Sell Transactions, Precigen, Inc.

2024-08-09Purchase
23.53M
7.203%
$0.85$20M-12.35%
2024-08-09PurchaseSVP, IP Affairs
58,823
0.018%
$0.85$50,000-12.35%
2023-12-28Saledirector
96,686
0.039%
$1.41$136,327-0.71%
2023-12-28Purchase
96,686
0.039%
$1.41$136,327-0.71%
2023-09-22Purchasedirector
25,000
0.0099%
$1.41$35,250-2.86%
2023-08-25SalePresident and CEO
76,969
0.0243%
$1.53$117,763-19.65%
2023-08-24SaleSVP, IP Affairs
8,891
0.0034%
$1.64$14,581-9.15%
2023-08-24SaleChief Legal Officer
10,947
0.0042%
$1.64$17,953-9.15%
2023-08-24SaleChief Financial Officer
9,045
0.0035%
$1.64$14,834-9.15%
2023-08-24SaleChief Operating Officer
5,388
0.0021%
$1.64$8,836-9.15%
2023-08-18SalePresident and CEO
55,855
0.0225%
$1.66$92,719-13.66%
2023-08-17SaleSVP, IP Affairs
8,741
0.0031%
$1.55$13,549-19.18%
2023-08-17SaleChief Legal Officer
10,762
0.0038%
$1.55$16,681-19.18%
2023-08-17SaleChief Financial Officer
8,893
0.0031%
$1.55$13,784-19.18%
2023-08-17SaleChief Operating Officer
5,298
0.0019%
$1.55$8,212-19.18%
2023-08-16Purchase
119,411
0.0466%
$1.51$180,311-8.38%
2023-08-15Purchase
380,589
0.1477%
$1.52$577,301-8.82%
2023-08-14Purchasedirector
400,000
0.1622%
$1.72$688,000-15.96%
2023-08-14Purchasedirector
570,345
0.2353%
$1.75$998,104-15.96%
2023-08-11SalePresident and CEO
41,436
0.0152%
$1.44$59,668-9.25%

Insider Historical Profitability

4.02%
KIRK RANDAL J
64547214
22.4345%
$0.907012+7.38%
Perez Jeffrey ThomasSVP, IP Affairs
743097
0.2583%
$0.90320<0.0001%
KINDLER JEFFREY Bdirector
238275
0.0828%
$0.9022<0.0001%
Ares Trading S.A.10 percent owner
20647152
7.1763%
$0.90167+52.74%
Sabzevari HelenPresident and CEO
1560004
0.5422%
$0.90123<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Patient Capital Management Llc$25.31M6.9117.45M+9.2%+$2.13M1.23
BlackRock$15.03M4.1110.36M-6.81%-$1.1M<0.0001
The Vanguard Group$9.81M2.686.77M+0.29%+$28,818.75<0.0001
Geode Capital Management$4.4M1.23.03M+0.32%+$13,904.17<0.0001
State Street$4.1M1.122.83M+5.25%+$204,329.67<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.